Query: Preclinical and clinical efficacy of small-molecule modulators of insulin signaling (e.g., IRS-1, PI3K, Akt activators) in ameliorating insulin resistance in PCOS animal models and primary human ovarian cell cultures, with ADME and toxicity assessments

Preclinical studies provide promising evidence that targeting insulin signaling components—including IRS-1, PI3K, and Akt—in PCOS models can improve insulin resistance, yet no clinical trials have been registered to directly assess small-molecule activators of these pathways in PCOS patients (Clinical Trials Search: small molecule insulin sensitizer AND polycystic ovary syndrome). Preclinical animal models, particularly in rats, and primary human ovarian cell cultures have been used to evaluate interventions that indirectly or directly modulate these signaling nodes.

For example, research using a PCOS rat model induced by letrozole and high‐fat diets demonstrated that multi‐component treatments, such as Liuwei Dihuang Pills, can reverse abnormal phosphorylation patterns of IRS‐1, PI3K, and Akt, thereby improving insulin sensitivity and ovarian function (qiu2020liuweidihuangpills pages 1-7). Although these herbal formulations contain multiple active constituents instead of pure small molecules, their modulation of the IRS-1/PI3K/Akt pathway supports the concept that direct targeting of these signaling proteins might yield therapeutic benefit. Similar mechanistic insights were derived from network pharmacology studies with saffron-derived compounds, which suggest that natural small molecules such as apocarotenoids could exert insulin sensitizing effects by targeting Akt and related signaling proteins in PCOS models (tiwari2023networkpharmacologybasedstrategic pages 11-12).

Evidence also comes from investigations into peptide-based molecules like a humanin analogue (HNG), which has been shown to restore the phosphorylation state of IRS-1, PI3K, and Akt in both rat granulosa cells and a human ovarian cell line (wang2021humaninalleviatesinsulin pages 9-10, wang2021humaninalleviatesinsulin pages 12-13). HNG administration resulted in decreased fasting plasma glucose and insulin levels as well as improved GLUT4 translocation, indicating that potentiation of the IRS1/PI3K/Akt cascade is efficacious in ameliorating insulin resistance at the ovarian level. Although HNG is a peptide and not a prototypical small-molecule activator, its success reinforces the potential utility of directly modulating these molecular targets in PCOS.

Concerning ADME (Absorption, Distribution, Metabolism, and Excretion) and toxicity assessments, the context reveals that detailed pharmacokinetic profiles and toxicity data of such small-molecule activators remain limited. Studies using classical insulin sensitizers like metformin and thiazolidinediones provide some insight into ADME aspects—for instance, metformin’s cellular uptake is mediated by OCT1 and is subject to genetic variability (dupont2016insulinsignallingand pages 12-13). However, these agents primarily improve peripheral insulin sensitivity and do not specifically act as direct activators of IRS-1, PI3K, or Akt in ovarian tissues. Likewise, preclinical studies with quercetin, a flavonoid inhibitor of PI3K, have demonstrated efficacy in lowering insulin and androgen levels in animal models (shah2016phosphatidylinositide3kinaseinhibition pages 1-2, shah2016phosphatidylinositide3kinaseinhibition pages 9-9), yet they lack detailed ADME and toxicity evaluations as applied to direct activators of the insulin signaling pathway.

In summary, while there is considerable preclinical evidence—primarily from animal models and primary ovarian cell cultures—demonstrating that modulation of IRS-1, PI3K, and Akt can ameliorate insulin resistance in PCOS, the translation into clinical development is hindered by a current lack of dedicated clinical trials and comprehensive ADME/toxicity data for these targeted small-molecule modulators (Clinical Trials Search: small molecule insulin sensitizer AND polycystic ovary syndrome, dupont2016insulinsignallingand pages 12-13). Further research is needed to isolate pure small-molecule activators, rigorously characterize their pharmacokinetic profiles, and evaluate their toxicity before clinical application in PCOS can be established.

References:
1. (qiu2020liuweidihuangpills pages 1-7): Zhixia Qiu, Jingjing Dong, Chu Xue, Xiaonan Li, Kang Liu, Baolin Liu, Jun Cheng, and Fang Huang. Liuwei dihuang pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through pi3k/akt signaling pathway. Journal of ethnopharmacology, pages 111965, Mar 2020. URL: https://doi.org/10.1016/j.jep.2019.111965, doi:10.1016/j.jep.2019.111965. This article has 93 citations and is from a peer-reviewed journal.

2. (tiwari2023networkpharmacologybasedstrategic pages 11-12): Anshuly Tiwari, Siddharth J. Modi, Aboli Girme, and Lal Hingorani. Network pharmacology-based strategic prediction and target identification of apocarotenoids and carotenoids from standardized kashmir saffron (crocus sativus l.) extract against polycystic ovary syndrome. Medicine, 102:e34514, Aug 2023. URL: https://doi.org/10.1097/md.0000000000034514, doi:10.1097/md.0000000000034514. This article has 4 citations and is from a peer-reviewed journal.

3. (wang2021humaninalleviatesinsulin pages 9-10): Yingying Wang, Zhengyan Zeng, Shuhua Zhao, Li Tang, Jin Yan, Nianyu Li, Liping Zou, Xiaorong Fan, Chengcheng Xu, Jin Huang, Wei Xia, Changhong Zhu, and Meng Rao. Humanin alleviates insulin resistance in polycystic ovary syndrome: a human and rat model–based study. Endocrinology, Mar 2021. URL: https://doi.org/10.1210/endocr/bqab056, doi:10.1210/endocr/bqab056. This article has 17 citations and is from a domain leading peer-reviewed journal.

4. (dupont2016insulinsignallingand pages 12-13): Joëlle Dupont and Rex J. Scaramuzzi. Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochemical Journal, 473:1483-1501, May 2016. URL: https://doi.org/10.1042/bcj20160124, doi:10.1042/bcj20160124. This article has 224 citations and is from a domain leading peer-reviewed journal.

5. (shah2016phosphatidylinositide3kinaseinhibition pages 1-2): Krushangi N. Shah and Snehal S. Patel. Phosphatidylinositide 3-kinase inhibition: a new potential target for the treatment of polycystic ovarian syndrome. Pharmaceutical Biology, 54:975-983, Jun 2016. URL: https://doi.org/10.3109/13880209.2015.1091482, doi:10.3109/13880209.2015.1091482. This article has 80 citations and is from a peer-reviewed journal.

6. (shah2016phosphatidylinositide3kinaseinhibition pages 9-9): Krushangi N. Shah and Snehal S. Patel. Phosphatidylinositide 3-kinase inhibition: a new potential target for the treatment of polycystic ovarian syndrome. Pharmaceutical Biology, 54:975-983, Jun 2016. URL: https://doi.org/10.3109/13880209.2015.1091482, doi:10.3109/13880209.2015.1091482. This article has 80 citations and is from a peer-reviewed journal.

7. (wang2021humaninalleviatesinsulin pages 12-13): Yingying Wang, Zhengyan Zeng, Shuhua Zhao, Li Tang, Jin Yan, Nianyu Li, Liping Zou, Xiaorong Fan, Chengcheng Xu, Jin Huang, Wei Xia, Changhong Zhu, and Meng Rao. Humanin alleviates insulin resistance in polycystic ovary syndrome: a human and rat model–based study. Endocrinology, Mar 2021. URL: https://doi.org/10.1210/endocr/bqab056, doi:10.1210/endocr/bqab056. This article has 17 citations and is from a domain leading peer-reviewed journal.
